Search

Your search keyword '"Croft, Brandon"' showing total 23 results

Search Constraints

Start Over You searched for: Author "Croft, Brandon" Remove constraint Author: "Croft, Brandon"
23 results on '"Croft, Brandon"'

Search Results

3. Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis

6. Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children

7. Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis

9. Abstract OT1-03-06: Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)

11. Navtemadlin (KRT-232) in combination with avelumab for patients with anti-PD-1/L1 treatment-naïve TP53 Merkel cell carcinoma (MCC)

13. An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer.

15. Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.

16. Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.

19. Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

21. Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children

22. Navtemadlin (KRT-232) in combination with avelumab for patients with anti-PD-1/L1 treatment-naïve TP53WTMerkel cell carcinoma (MCC)

23. Ubiquitin-Proteasome System in Neurodegenerative Disorders.

Catalog

Books, media, physical & digital resources